Compare Bristol-Myers Squibb Co (BMY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Monster Beverage Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while Monster Beverage Corp trades at $98.45 (market cap $95.85B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| BMY | MNST | |
|---|---|---|
Market Cap | $116.30B | $95.85B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $98.01 |
52-Week Low | $42.60 | $58.65 |
Enterprise Value | $152.24B | $94.15B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Monster Beverage (MNST) trades at $97.07, down 0.33% on the day, with strong technical bullish signals from moving averages and a neutral RSI. The company demonstrates robust fundamentals with 2025 revenue of $8.29B, net income of $1.91B, and consistent earnings beats. Recent corporate actions include a 2-for-1 stock split effective August 11, 2026, reflecting management confidence in continued growth prospects.
MNST presents a compelling growth story with accelerating international expansion and product innovation driving market share gains. However, premium valuation multiples (P/E 46.89, P/S 10.89) create vulnerability to earnings disappointments. Analyst consensus remains positive with 53% buy ratings, though the $94.60 price target suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
